Page 10 - Junshi Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Junshi Biosciences Announces Toripalimab as Perioperative

SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading.

United statesUnited kingdomSan franciscoJunshi bioscienceJunshi biosciencesZhi liIr teamWorld health organizationDrug administrationData monitoring committeeRegulatory agencyBlind independent pathology review committeeNational reimbursement drug listEuropean medicines agencyPr teamInstitute of microbiology the chinese academy

Junshi Biosciences Announces Acceptance of NDA for VV116 in

SHANGHAI, China, Jan. 17, 2023 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading.

United statesSan franciscoJunshi bioscienceJunshi biosciencesZhi liIr teamNational medical products administrationPr teamInstitute of microbiology the chinese academyShanghai junshi biosciences co ltdDeuremidevir hydrobromide tabletsChinese academyEmergency use authorizationsHong kong stock exchange 1877 hkJunshi biosciences

Junshi Biosciences Announces Toripalimab as Perioperative Treatment for Operable NSCLC Patients Met Primary Endpoint in Phase 3 Clinical Study

SHANGHAI, China, Jan. 18, 2023 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated

United statesUnited kingdomJunshi bioscienceJunshi biosciencesZhi liIr teamWorld health organizationDrug administrationData monitoring committeeRegulatory agencyBlind independent pathology review committeeNational reimbursement drug listEuropean medicines agencyPr teamShanghai junshi biosciences co ltdIndependent data monitoring committee

Outlook on the Nasopharyngeal Cancer Global Market to 2028 - Featuring Biocon, Bristol-Myers Squibb, Cyclacel Pharmaceuticals and Eli Lilly and Co Among Others

/PRNewswire/ The "Global Nasopharyngeal Cancer Market Research and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com s offering. The.

United statesUnited kingdomRepublic ofSouth koreaSouth koreanJunshi bioscienceEli lillyLaura woodCyclacel pharmaceuticals incGlaxosmithkline plcMerck co incGlobal nasopharyngeal cancer market researchInternational agency for research on cancerPfizer incBiocon ltdBristol myers squibb co

Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Versus PAXLOVID for Adults at High Risk for Progression to Severe COVID-19

Junshi Biosciences Announces NEJM Publication of Results of Phase 3 Study of VV116 Versus PAXLOVID for Adults at High Risk for Progression to Severe COVID-19
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesTong renJunshi bioscienceJunshi bioscienceszhi liJunshi biosciencesActa pharmacologica sinicaXinjiang technical institute of physicsShanghai university of traditional chinese medicineVigonvita life sciences co ltdPr teamInstitute of microbiology the chinese academyShanghai public health clinical centreGlobal researchShanghai jiao tong university school of medicineJunshi biosciences contact informationir team